Keeping An Eye On Regeneron: What's Next To Drive Growth

 
• By Jessica Merrill

Regeneron is looking to expansion of Eylea to diabetic retinopathy and Dupixent to asthma and other indications to drive mid-term growth. The firm is poised to file a PD-1 inhibitor with FDA in Q1.

Man with report

More from Earnings

More from Business